Drug intelligence / Profile preview

cerlapirdine

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Cerlapirdine is a selective and potent full antagonist of the serotonin 6 (5-HT6) receptor. It was developed by Wyeth and later Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. The drug demonstrated a trend toward efficacy in phase II clinical trials for Alzheimer's disease, with a favorable side effect profile and no serious adverse events reported. However, development was discontinued after 2011 with no further advancement in clinical trials[1][2][3][4][5]. Cerlapirdine belongs to the class of antidementia agents.

Other names: cerlapirdine hydrochlorideSAM-531 free baseSAM531 free baseSAM 531 free base

Targets

HTR6 (5-hydroxytryptamine receptor 6)

Beyond the preview

Go deeper on cerlapirdine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cerlapirdine.

Explore the full profile